<DOC>
	<DOCNO>NCT00469820</DOCNO>
	<brief_summary>RATIONALE : Vaccines make patient 's cancer cell may help body build effective immune response kill cancer cell . Giving vaccine therapy together donor lymphocyte infusion stem cell transplant patient 's brother sister may kill cancer cell remain transplant . PURPOSE : This clinical trial study side effect , best dose , well vaccine therapy without donor lymphocyte infusion work treat patient acute myeloid leukemia , acute lymphoblastic leukemia , multiple myeloma undergo donor stem cell transplant .</brief_summary>
	<brief_title>Vaccine Therapy With Without Donor Lymphocyte Infusion Treating Patients With Acute Myeloid Leukemia , Acute Lymphoblastic Leukemia , Multiple Myeloma Undergoing Donor Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : - Determine time relapse overall survival patient high-risk acute myeloid leukemia , acute lymphoblastic leukemia , multiple myeloma treat autologous tumor cell vaccine without donor lymphocyte infusion HLA-matched related sibling nonmyeloablative hematopoietic stem cell transplantation . - Evaluate safety tolerability regimen patient . - Determine maximum tolerate dose donor lymphocyte infusion patient . OUTLINE : Patients undergo collection tumor cell production cancer cell vaccine undergo HLA-matched related sibling nonmyeloablative hematopoietic stem cell transplantation ( HSCT ) . Patients receive cancer cell vaccine without donor lymphocyte infusion . The donor lymphocytes obtain relative donated stem cell HSCT . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed diagnosis 1 following : Acute myeloid leukemia ( AML ) , meet follow criterion : Relapsed disease AML arise myelodysplastic syndrome Primary refractory disease De novo AML highrisk feature Acute lymphoblastic leukemia ( ALL ) , meet follow criterion : De novo ALL Philadelphia chromosome positive ( 4,11 ) cytogenetic feature Relapsed disease Multiple myeloma ( need treatment ) Planning undergo HLAmatched relate sibling nonmyeloablative hematopoietic stem cell transplantation PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
</DOC>